porcilis pcv m hyo
intervet international b.v. - porcine circovirus type 2 (pcv2) orf2 subunit antigen, mycoplasma hyopneumoniae j strain inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - pigs (for fattening) - for the active immunisation of pigs to reduce viraemia, virus load in lungs and lymphoid tissues, virus shedding caused by porcine circovirus type 2 (pcv2) infection, and severity of lung lesions caused by mycoplasma hyopneumoniae infection. to reduce the loss of daily weight gain during the finishing period in face of infections with mycoplasma hyopneumoniae and/or pcv2 (as observed in field studies)
ingelvac circoflex suspension for injection in pigs
boehringer ingelheim animal health australia pty. ltd. - porcine circovirus type 2 orf2 protein; carbomer - misc. vaccines or anti sera - porcine circovirus type 2 orf2 protein vaccine-viral active 1.0 ml/do; carbomer ungrouped other 1.0 mg - immunotherapy - pigs - see label for type - disease control
porcilis pcv id formulation: each 0.2 ml (dose) contains: porcine circovirus type 2 (orf2)> 1436 au au-antigenic units emulsion for injection (id)
msd animal health (phils.), inc.; distributor: msd animal health (phils.), inc. - inactivated porcine circovirus (pcv) virus vaccine (vet.) - emulsion for injection (id) - formulation: each 0.2 ml (dose) contains: porcine circovirus type 2 (orf2)> 1436 au au-antigenic units
suvaxyn circo+mh rtu
zoetis belgium sa - inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2 orf2 protein, inactivated mycoplasma hyopneumoniae, strain p-5722-3 - inactivated viral and inactivated bacterial vaccines - pigs - for active immunisation of pigs from 3 weeks of age against porcine circovirus type 2 (pcv2) to reduce viral load in blood and lymphoid tissues and fecal shedding caused by infection with pcv2.for active immunisation of pigs over the age of 3 weeks against mycoplasma hyopneumoniae to reduce lung lesions caused by infection with m. hyopneumoniae.
ingelvac circoflex-mycoflex processed under fda memorandum circular 2021-001. formulation: each 2 ml (dose) contains: porcine circovirus type 2, orf 2........................>1 rp mesomycoplasma hyopneumoniae (b-3745 isolate, j strain) .........> 1rp rp - relative potency suspension for injection (im)
boehringer ingelheim animal health philippines, inc.; distributor: boehringer ingelheim animal health philippines, inc. - inactivated porcine circovirus type 2 (pcv2) mesomycoplasma hyopneumoniae vaccine (vet.) - suspension for injection (im) - processed under fda memorandum circular 2021-001. formulation: each 2 ml (dose) contains: porcine circovirus type 2, orf 2........................>1 rp mesomycoplasma hyopneumoniae (b-3745 isolate, j strain) .........> 1rp rp - relative potency
porcine circovirus type 1-type 2b chimera inactivated
zoetis australia pty ltd - porcine circovirus type 1-type 2b chimera inactivated - unknown - porcine circovirus type 1-type 2b chimera inactivated vaccine-antigen/antibody active 0.0 - active constituent